Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother (2008) 5.04

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother (2008) 2.39

Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog (2010) 1.65

In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother (2009) 1.64

Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis (2009) 1.64

Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis (2011) 1.52

Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis (2012) 1.49

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A (2009) 1.48

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses (2013) 1.37

Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis (2011) 1.31

Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One (2009) 1.30

Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One (2007) 1.26

Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20

Oseltamivir-resistant influenza a viruses circulating in Japan. J Clin Microbiol (2009) 1.14

Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS One (2009) 1.13

The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One (2013) 1.12

Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res (2013) 1.12

Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog (2010) 1.11

Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One (2009) 1.10

Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J (2011) 1.10

Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother (2010) 1.09

CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother (2009) 1.04

Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem (2010) 1.01

Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A (2012) 1.00

Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother (2011) 0.95

Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis (2011) 0.92

Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother (2011) 0.91

Clinical Implications of Antiviral Resistance in Influenza. Viruses (2015) 0.90

Use of rapid tests and antiviral medications for influenza among primary care providers in the United States. Influenza Other Respir Viruses (2009) 0.90

Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother (2014) 0.88

A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance. Antimicrob Agents Chemother (2013) 0.86

Epidemiological and Evolutionary Dynamics of Influenza B Viruses in Malaysia, 2012-2014. PLoS One (2015) 0.85

News about influenza B drug resistance that cannot be ignored. JAMA (2007) 0.85

Adamantane-resistant influenza infection during the 2004-05 season. Emerg Infect Dis (2008) 0.84

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. Antimicrob Agents Chemother (2014) 0.84

Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother (2010) 0.84

I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses. PLoS One (2013) 0.83

Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J Virol (2015) 0.81

Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis. Eur J Clin Microbiol Infect Dis (2011) 0.80

Mitigation approaches to combat the flu pandemic. J Glob Infect Dis (2009) 0.80

In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Clin Microbiol Infect (2010) 0.79

Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013. PLoS One (2015) 0.78

Genetic characterisation of influenza B viruses detected in Singapore, 2004 to 2009. BMC Res Notes (2014) 0.78

Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient. J Clin Microbiol (2012) 0.78

Characterization of potent fusion inhibitors of influenza virus. PLoS One (2015) 0.77

Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. Antimicrob Agents Chemother (2015) 0.77

NXT1, a Novel Influenza A NP Binding Protein, Promotes the Nuclear Export of NP via a CRM1-Dependent Pathway. Viruses (2016) 0.76

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens. Antimicrob Agents Chemother (2013) 0.76

A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. J Infect Dis (2014) 0.75

Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening. J Virol (2016) 0.75

Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015. PLoS One (2017) 0.75

Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral Resistance. PLoS Comput Biol (2016) 0.75

Outbreak of antiviral drug-resistant influenza a in long-term care facility, Illinois, USA, 2008. Emerg Infect Dis (2009) 0.75

Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother (2013) 0.75

Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011. Indian J Med Res (2014) 0.75

The Functional Study of the N-Terminal Region of Influenza B Virus Nucleoprotein. PLoS One (2015) 0.75

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (2009) 14.59

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature (2012) 14.17

Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature (2009) 11.34

Avian flu: influenza virus receptors in the human airway. Nature (2006) 11.28

Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40

Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (2004) 8.62

Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature (2006) 7.56

Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66

Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11

PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology (2004) 5.96

Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol (2005) 5.28

Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J Virol (2006) 5.26

Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature (2006) 4.52

Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog (2007) 4.49

A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2011) 4.22

Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol (2009) 4.20

Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature (2008) 4.18

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology (2004) 4.16

Inhibition of Lassa and Marburg virus production by tetherin. J Virol (2008) 3.98

Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol (2011) 3.88

Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77

Characterization of H7N9 influenza A viruses isolated from humans. Nature (2013) 3.71

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69

Gain-of-function experiments on H7N9. Science (2013) 3.67

Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog (2010) 3.65

Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62

The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science (2012) 3.50

Selective incorporation of influenza virus RNA segments into virions. Proc Natl Acad Sci U S A (2003) 3.45

Semi-rational engineering of a coral fluorescent protein into an efficient highlighter. EMBO Rep (2005) 3.45

Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis (2006) 3.27

FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J Clin Invest (2008) 3.25

The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19

Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet (2011) 3.19

Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J (2002) 3.06

The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu Rev Microbiol (2005) 2.89

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83

A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J Virol (2007) 2.80

Characterization of H5N1 influenza A viruses isolated during the 2003-2004 influenza outbreaks in Japan. Virology (2005) 2.77

Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis (2006) 2.72

Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol (2006) 2.70

Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes. J Virol (2003) 2.67

Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. PLoS Pathog (2009) 2.62

Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication. J Virol (2006) 2.60

Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog (2010) 2.60

Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58

Human infection with highly pathogenic H5N1 influenza virus. Lancet (2008) 2.57

Transparent development of the WHO rapid advice guidelines. PLoS Med (2007) 2.57

Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol (2005) 2.55

PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun (2012) 2.55

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54

Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J Virol (2005) 2.45

Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog (2009) 2.44

Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44

Selection of H5N1 influenza virus PB2 during replication in humans. J Virol (2009) 2.42

Single-balloon versus double-balloon endoscopy for achieving total enteroscopy: a randomized, controlled trial. Gastrointest Endosc (2011) 2.39

Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34

An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A (2005) 2.33

Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32

High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol (2010) 2.29

Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24

A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: a retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest Endosc (2009) 2.24

Pause on avian flu transmission research. Science (2012) 2.24

Differences in cytokine production in human macrophages and in virulence in mice are attributable to the acidic polymerase protein of highly pathogenic influenza A virus subtype H5N1. J Infect Dis (2012) 2.24

Cellular networks involved in the influenza virus life cycle. Cell Host Microbe (2010) 2.23

Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol (2003) 2.19

Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol (2005) 2.09

Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer (2011) 2.09

Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09